Enrollment

REBETOL®
(ribavirin)
CRIXIVAN®
(indinavir sulfate)
ISENTRESS®
(raltegravir)
GARDASIL®
[Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recombinant Vaccine]
GARDASIL®9
[human papillomavirus 9-valent vaccine, recombinant]
JANUVIA®
(sitagliptin phosphate)
JANUMET®
(sitagliptin/metformin HCl)
MAXALT®
(rizatriptan benzoate)
SINGULAIR®
(montelukast sodium)
VARICELLA ZOSTER VIRUS-CONTAINING VACCINES


 


MAXALT Pregnancy Registry

Please note that the Pregnancy Registry for MAXALT is now closed to new enrollment.

Healthcare providers are encouraged to report any prenatal exposure to MAXALT. For questions related to exposure to MAXALT during pregnancy or to report new cases of exposure to MXALT during pregnancy, please contact Merck’s National Service Center at 1-877-888-4231.

The Pregnancy Registry for MAXALT discontinued new patient enrollment on October 1, 2019. Follow-up of patients currently enrolled will continue until the last patient data is collected or it is determined that the patient is lost to follow-up.

Registry personnel wish to convey their gratitude to the women and health care providers who reported cases of exposure during pregnancy and completed registry questionnaires.

 


CRIXIVAN  |  GARDASIL  |  GARDASIL 9  |  ISENTRESS  |  JANUVIA  |  JANUMET  |  MAXALT  |  PROQUAD  |  SINGULAIR  |  REBETOL  |  VARIVAX  |  ZOSTAVAX  |  REBETOL  | 
Enrollment  |  Home  |  Privacy Policy

Copyright © 2012 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. All rights reserved.